Lung Cancer

As Canadian wildfire smoke blankets much of the U.S., here's what people with cancer and cancer survivors should know about the potential health risks.

After reaching remission from stage 3B non-small cell lung cancer, one survivor shares the emotional journey of healing, hope and finding a new normal.

Join LiveLung's Charlotte meeting to learn how The White Ribbon Project is raising lung cancer awareness, reducing stigma and supporting patients.

AURORA, a phase 3 trial, is testing aglatimagene besadenovec plus Keytruda in patients with lung cancer who progressed on immunotherapy.

A kidney cancer survivor reflects on National Doctors Day and how trust with his oncologist, Dr. Toni Choueiri, became a lifelong bond.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.

Study data shows Ibtrozi provides rapid symptom relief and stable brain health for patients with advanced ROS1-positive lung cancer.

Patients with EGFR exon 20-positive NSCLC had longer progression-free survival with Zegfrovy than chemotherapy.

ASCO 2026 will highlight biomarker-driven lung cancer care, targeted therapies, ADCs and phase 3 trials shaping precision oncology advances.

A lung and breast cancer survivor shares how genetic history, supporting her daughter and leading a support group helped her keep smiling.

A SEER-Medicare study found nearly half of older patients with metastatic non–small cell lung cancer never received systemic therapy.

New therapies are beginning to crack KRAS, offering tumor shrinkage and longer survival as researchers work to overcome resistance.

Dietitian Stephanie Meyers shared practical strategies at the LiveLung SCLC Patient Summit to help patients manage appetite loss and digestive issues.

A man with small cell lung cancer describes carboplatin-related hearing loss, fatigue and daily challenges that have reshaped his life, while holding onto perspective and resilience.

Gotistobart improved responses and survival versus docetaxel in pretreated squamous NSCLC, offering a potential chemo-free option with durable benefit in some patients.

Gotistobart reduced risk of death by 54% and doubled 12-month survival vs chemotherapy in advanced squamous NSCLC after prior treatment.

Libtayo improved survival and safety outcomes vs chemotherapy in advanced NSCLC, with 23% of patients alive at six years in the EMPOWER-Lung 1 trial.

Nuvalent submitted an NDA for neladalkib to the FDA for patients with previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 trial data showing activity.

New research shows adults over 80 with early-stage lung cancer can achieve surgical outcomes and quality of life comparable to younger patients.

New ELCC 2026 data show longer survival, better brain metastases control and more personalized treatment options for patients with lung cancer.

Eight patients with NSCLC treated with ateganosine plus Libtayo had over 2-year survival after prior therapies, based on phase 2 THIO-101 trial data.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.